Mind Medicine (STU:MMQ) Pre-Tax Income : €-100.99 Mil (TTM As of Dec. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Mind Medicine Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. Mind Medicine's pretax income for the three months ended in Dec. 2024 was €-33.18 Mil. Its pretax income for the trailing twelve months (TTM) ended in Dec. 2024 was €-100.99 Mil. Mind Medicine's pretax margin was %.

Mind Medicine Pre-Tax Income Historical Data

The historical data trend for Mind Medicine's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mind Medicine Pre-Tax Income Chart

Mind Medicine Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

Pre-Tax Income

-27.90

-83.36

-53.62

-87.79

-103.79

Mind Medicine Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Pre-Tax Income	Get a 7-Day Free Trial															-21.88	-50.05	-5.44	-12.33	-33.18

Competitive Comparison of Mind Medicine's Pre-Tax Income

For the Biotechnology subindustry, Mind Medicine's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mind Medicine's Pre-Tax Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mind Medicine's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where Mind Medicine's Pre-Tax Income falls into.

Save Embed

;

Save Embed

;

Mind Medicine Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

Mind Medicine's Pretax Income for the fiscal year that ended in Dec. 2024 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-99.24	+	-13.406	+	-2.18	+	11.038	+	1.4210854715202E-14
	=	-103.79

Mind Medicine's Pretax Income for the quarter that ended in Dec. 2024 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-31.001	+	-4.681	+	-0.626	+	3.131	+	-0.00099999999999767
	=	-33.18

Pre-Tax Income for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-100.99 Mil.

Mind Medicine (STU:MMQ) Pre-Tax Income Explanation

Mind Medicine's Pretax Margin for the quarter that ended in Dec. 2024 is calculated as

Pretax Margin	=	Pretax Income	/	Revenue
	=	-33.178	/	0
	=	%

Mind Medicine Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of Mind Medicine's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Mind Medicine Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mind Medicine Inc (STU:MMQ) » Definitions » Pre-Tax Income

Comparable Companies

Traded in Other Exchanges

MNMD:USA MMQ:Germany

Address

One World Trade Center, Suite 8500, New York, NY, USA, 10007

Website

https://www.mindmed.co

Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).

Mind Medicine Headlines

No Headlines